cTnT shows a response to tofersen treatment similar to the previously reported effect on NfL in serum and CSF, thus suggesting cTnT may have use as a complementary biomarker for detecting therapeutic effects in ALS patients. This evidence concerns the gene NEFL and amyotrophic lateral sclerosis.